These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
181 related items for PubMed ID: 23069925
1. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer. Schroeder RP, De Blois E, De Ridder CM, Van Weerden WM, Breeman WA, de Jong M. Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):468-75. PubMed ID: 23069925 [Abstract] [Full Text] [Related]
2. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, Groen HC, Reneman S, de Blois E, Breeman WA, de Jong M. Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398 [Abstract] [Full Text] [Related]
3. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer. Carlucci G, Ananias HJ, Yu Z, Hoving HD, Helfrich W, Dierckx RA, Liu S, de Jong IJ, Elsinga PH. Mol Pharm; 2013 May 06; 10(5):1716-24. PubMed ID: 23590837 [Abstract] [Full Text] [Related]
4. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, de Jong M. Int J Cancer; 2010 Jun 15; 126(12):2826-34. PubMed ID: 19876914 [Abstract] [Full Text] [Related]
5. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, Xing L, Chen X. J Nucl Med; 2006 Mar 15; 47(3):492-501. PubMed ID: 16513619 [Abstract] [Full Text] [Related]
6. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice. Ho CL, Chen LC, Lee WC, Chiu SP, Hsu WC, Wu YH, Yeh CH, Stabin MG, Jan ML, Lin WJ, Lee TW, Chang CH. Cancer Biother Radiopharm; 2009 Aug 15; 24(4):435-43. PubMed ID: 19694578 [Abstract] [Full Text] [Related]
7. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Schroeder RP, Müller C, Reneman S, Melis ML, Breeman WA, de Blois E, Bangma CH, Krenning EP, van Weerden WM, de Jong M. Eur J Nucl Med Mol Imaging; 2010 Jul 15; 37(7):1386-96. PubMed ID: 20182713 [Abstract] [Full Text] [Related]
9. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS. J Nucl Med; 2004 Aug 15; 45(8):1390-7. PubMed ID: 15299066 [Abstract] [Full Text] [Related]
13. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE. J Nucl Med; 2009 Dec 15; 50(12):2017-24. PubMed ID: 19910427 [Abstract] [Full Text] [Related]
14. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs. Carlucci G, Kuipers A, Ananias HJ, de Paula Faria D, Dierckx RA, Helfrich W, Rink R, Moll GN, de Jong IJ, Elsinga PH. Peptides; 2015 May 15; 67():45-54. PubMed ID: 25797109 [Abstract] [Full Text] [Related]
15. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [68Ga]Ga-NODAGA-AMBA and [44Sc]Sc-NODAGA-AMBA. Kálmán-Szabó I, Szabó JP, Arató V, Dénes N, Opposits G, Jószai I, Kertész I, Képes Z, Fekete A, Szikra D, Hajdu I, Trencsényi G. Int J Mol Sci; 2022 Sep 02; 23(17):. PubMed ID: 36077458 [Abstract] [Full Text] [Related]
16. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ. Bioconjug Chem; 2003 Sep 02; 14(4):756-63. PubMed ID: 12862428 [Abstract] [Full Text] [Related]
17. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist. Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA. J Nucl Med; 2017 Jan 02; 58(1):29-35. PubMed ID: 27516447 [Abstract] [Full Text] [Related]
18. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Ferro-Flores G, Arteaga de Murphy C, Rodriguez-Cortés J, Pedraza-López M, Ramírez-Iglesias MT. Nucl Med Commun; 2006 Apr 02; 27(4):371-6. PubMed ID: 16531924 [Abstract] [Full Text] [Related]
19. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT. Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, Nock BA, de Jong M, Baum RP. Eur J Nucl Med Mol Imaging; 2016 May 02; 43(5):964-973. PubMed ID: 26631238 [Abstract] [Full Text] [Related]
20. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, Maecke HR. Cancer Res; 2004 Sep 15; 64(18):6707-15. PubMed ID: 15374988 [Abstract] [Full Text] [Related] Page: [Next] [New Search]